Algo TX/IOCPC23007/ Gewandter
Basic Study Information
Purpose:
The purpose of this clinical trial is to compare the efficacy of twice daily applications
of ATX01 (10% & 15%) versus placebo during a 12-week treatment period in treating
chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivor patients.
Location: University of Rochester Medical Center
Lead Researcher (Principal Investigator)
Lead Researcher:
Jennifer Gewandter
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search